Cerebral small vessel disease is a common cause of cognitive impairment. Remote ischemic pre-conditioning (RIC) is a technique to induce brief periods of limb ischemia-reperfusion that is hypothesized to increase tolerance of the brain to hypoperfusion and increase cerebral blood flow. Patients with cognitive impairment, preserved basic activities of daily living, and brain computed tomography (CT) or magnetic resonance imaging (MRI) evidence of confluent white matter hyperintensities or multiple brain infarcts will be randomized to either RIC performed once a day on one arm, or twice per day on one arm, for 30 days, to test tolerability and effects on MRI markers of blood flow.
Cerebral small vessel disease (cSVD) accounts for 20-25% of all strokes and is the most common cause of vascular cognitive impairment (VCI) as well as a major contributor to mixed dementia, potentially interacting with Alzheimer's disease. Remote ischemic pre-conditioning (RIC) is a technique to induce brief periods of limb ischemia-reperfusion that is hypothesized to increase tolerance of the brain to hypoperfusion. This is a prospective, open-label randomized controlled clinical trial with blinded endpoint assessment (PROBE). Participants that complete a 14-day run-in period will be randomized to 30 days of either: a) RIC performed once per day on one arm, or b) RIC performed twice per day on one arm. Each RIC session will consist of 4 cycles of unilateral upper arm ischemia for 5 minutes followed by reperfusion for another 5 minutes, administered by modified blood pressure monitor (under an Investigational Trail Authorization from Health Canada). The primary outcome is tolerability, defined as the proportion in each trial arm that complete 80% or more of the assigned RIC sessions. Secondary outcomes will include pain scores, cognition, and MRI markers of cerebral blood flow and white matter integrity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
24
Remote ischemic conditioning therapy to the upper arm will be delivered by an automated device (RIC VCI) manufactured by Seagull Aps (Denmark).
Foothills Medical Centre
Calgary, Alberta, Canada
RECRUITINGAdherence
Proportion completing 80% or more sessions.
Time frame: 30 days
Discontinuation
Cessation of device use
Time frame: 30 days
Randomization
Proportion completing the run-in period and proceeding to randomization
Time frame: 14 days
Physical examination
Proportion with signs of arm soft tissue or neurovascular injury
Time frame: 30 days
Arm deep venous thrombosis
Arm deep venous thrombosis
Time frame: 30 days
Pain
Mean peak and end-cycle pain levels reported using the Numeric Rating Scale for pain (based on subjective report, ranging from 0 \[no pain\] to 10 \[worst possible pain\]).
Time frame: 30 days
MRI cerebral blood flow
Change in cerebral blood flow measured by arterial spin label MRI
Time frame: 30 days and 90 days
MRI white matter hyperintensity volume
Change in white matter hyperintensity volume on FLAIR
Time frame: 30 days and 90 days
MRI diffusion tensor imaging
Change in MRI peak skeletonized mean diffusivity
Time frame: 30 days and 90 days
Global cognition
Change in Montreal Cognitive Assessment
Time frame: 30 days and 90 days
Neuropsychological tests
Change in Trail-Making A and B
Time frame: 30 days and 90 days
Neuropsychiatric symptoms
Change in Mild Behavioural Impairment Checklist
Time frame: 30 days and 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.